Literature DB >> 20846345

Fibrogenic cell phenotype modifications during remodelling of normal and pathological human liver in cultured slices.

Christelle Guyot1, Sébastien Lepreux, Chantal Combe, Vincent Sarrazy, Fabrice Billet, Charles Balabaud, Paulette Bioulac-Sage, Alexis Desmoulière.   

Abstract

BACKGROUND: The debate concerning the potential remodelling and/or reversibility of cirrhotic lesions and biliary fibrosis is still open. AIMS/
METHODS: In this work, we have used the precision-cut liver slice (PCLS) model, which maintains cell-cell and cell-matrix interactions to study, by immunohistochemistry, the behaviour of the different fibrogenic cells, i.e. hepatic stellate cells (HSC) and portal fibroblasts, in cultured (for 1 week) PCLS derived from normal and fibrotic human livers.
RESULTS: In normal liver, before and after culture, α-smooth muscle (SM) actin was present only in the vessel walls. Platelet-derived growth factor (PDGF) receptor-β was expressed before and after culture by portal fibroblasts, and appeared after culture in HSC. Before culture, CD 34 was not expressed in parenchyma, but appeared after culture in sinusoidal endothelial cells. In cirrhotic lesions, before culture, α-SM actin, PDGF receptor-β and Thy-1 were expressed in septa; after culture, α-SM actin expression disappeared but the expression of the PDGF receptor-β and Thy-1 was maintained. In cholestatic liver specimens, α-SM actin, PDGF receptor-β and Thy-1 expression, which was present before culture in enlarged portal areas, disappeared after culture, and apoptosis was detected. In the parenchyma of both cirrhotic and cholestatic livers, the expression of the PDGF receptor-β and of CD 34, which was not observed before culture, was present in HSC and sinusoidal endothelial cells, respectively, after culture.
CONCLUSIONS: These results indicate that during remodelling of pathological tissues in cultured liver slices, the myofibroblastic cells derived from HSC or from portal fibroblasts show different behaviours, suggesting different mechanisms of activation/deactivation.
© 2010 John Wiley & Sons A/S.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20846345     DOI: 10.1111/j.1478-3231.2010.02342.x

Source DB:  PubMed          Journal:  Liver Int        ISSN: 1478-3223            Impact factor:   5.828


  19 in total

Review 1.  Recent developments in myofibroblast biology: paradigms for connective tissue remodeling.

Authors:  Boris Hinz; Sem H Phan; Victor J Thannickal; Marco Prunotto; Alexis Desmoulière; John Varga; Olivier De Wever; Marc Mareel; Giulio Gabbiani
Journal:  Am J Pathol       Date:  2012-03-02       Impact factor: 4.307

Review 2.  Prevention of hepatocellular carcinoma: potential targets, experimental models, and clinical challenges.

Authors:  Yujin Hoshida; Bryan C Fuchs; Kenneth K Tanabe
Journal:  Curr Cancer Drug Targets       Date:  2012-11-01       Impact factor: 3.428

3.  A microfluidic platform for functional testing of cancer drugs on intact tumor slices.

Authors:  A D Rodriguez; L F Horowitz; K Castro; H Kenerson; N Bhattacharjee; G Gandhe; A Raman; R J Monnat; R Yeung; R C Rostomily; A Folch
Journal:  Lab Chip       Date:  2020-04-09       Impact factor: 6.799

Review 4.  Human hepatic stellate cell isolation and characterization.

Authors:  Linshan Shang; Mojgan Hosseini; Xiao Liu; Tatiana Kisseleva; David Allen Brenner
Journal:  J Gastroenterol       Date:  2017-11-01       Impact factor: 7.527

5.  Origin of myofibroblasts in the fibrotic liver in mice.

Authors:  Keiko Iwaisako; Chunyan Jiang; Mingjun Zhang; Min Cong; Thomas Joseph Moore-Morris; Tae Jun Park; Xiao Liu; Jun Xu; Ping Wang; Yong-Han Paik; Fanli Meng; Masataka Asagiri; Lynne A Murray; Alan F Hofmann; Takashi Iida; Christopher K Glass; David A Brenner; Tatiana Kisseleva
Journal:  Proc Natl Acad Sci U S A       Date:  2014-07-29       Impact factor: 11.205

Review 6.  Engineering liver.

Authors:  Linda G Griffith; Alan Wells; Donna B Stolz
Journal:  Hepatology       Date:  2014-05-19       Impact factor: 17.425

Review 7.  Recent advances in 2D and 3D in vitro systems using primary hepatocytes, alternative hepatocyte sources and non-parenchymal liver cells and their use in investigating mechanisms of hepatotoxicity, cell signaling and ADME.

Authors:  Patricio Godoy; Nicola J Hewitt; Ute Albrecht; Melvin E Andersen; Nariman Ansari; Sudin Bhattacharya; Johannes Georg Bode; Jennifer Bolleyn; Christoph Borner; Jan Böttger; Albert Braeuning; Robert A Budinsky; Britta Burkhardt; Neil R Cameron; Giovanni Camussi; Chong-Su Cho; Yun-Jaie Choi; J Craig Rowlands; Uta Dahmen; Georg Damm; Olaf Dirsch; María Teresa Donato; Jian Dong; Steven Dooley; Dirk Drasdo; Rowena Eakins; Karine Sá Ferreira; Valentina Fonsato; Joanna Fraczek; Rolf Gebhardt; Andrew Gibson; Matthias Glanemann; Chris E P Goldring; María José Gómez-Lechón; Geny M M Groothuis; Lena Gustavsson; Christelle Guyot; David Hallifax; Seddik Hammad; Adam Hayward; Dieter Häussinger; Claus Hellerbrand; Philip Hewitt; Stefan Hoehme; Hermann-Georg Holzhütter; J Brian Houston; Jens Hrach; Kiyomi Ito; Hartmut Jaeschke; Verena Keitel; Jens M Kelm; B Kevin Park; Claus Kordes; Gerd A Kullak-Ublick; Edward L LeCluyse; Peng Lu; Jennifer Luebke-Wheeler; Anna Lutz; Daniel J Maltman; Madlen Matz-Soja; Patrick McMullen; Irmgard Merfort; Simon Messner; Christoph Meyer; Jessica Mwinyi; Dean J Naisbitt; Andreas K Nussler; Peter Olinga; Francesco Pampaloni; Jingbo Pi; Linda Pluta; Stefan A Przyborski; Anup Ramachandran; Vera Rogiers; Cliff Rowe; Celine Schelcher; Kathrin Schmich; Michael Schwarz; Bijay Singh; Ernst H K Stelzer; Bruno Stieger; Regina Stöber; Yuichi Sugiyama; Ciro Tetta; Wolfgang E Thasler; Tamara Vanhaecke; Mathieu Vinken; Thomas S Weiss; Agata Widera; Courtney G Woods; Jinghai James Xu; Kathy M Yarborough; Jan G Hengstler
Journal:  Arch Toxicol       Date:  2013-08-23       Impact factor: 5.153

8.  An in vitro model of human acute ethanol exposure that incorporates CXCR3- and CXCR4-dependent recruitment of immune cells.

Authors:  Sumera Karim; Evaggelia Liaskou; Samuel Hadley; Janine Youster; Jeff Faint; David H Adams; Patricia F Lalor
Journal:  Toxicol Sci       Date:  2013-01-08       Impact factor: 4.849

Review 9.  The role of the myofibroblast in tumor stroma remodeling.

Authors:  Marcela Otranto; Vincent Sarrazy; Frédéric Bonté; Boris Hinz; Giulio Gabbiani; Alexis Desmoulière
Journal:  Cell Adh Migr       Date:  2012-05-01       Impact factor: 3.405

10.  The myofibroblast, multiple origins for major roles in normal and pathological tissue repair.

Authors:  Ludovic Micallef; Nicolas Vedrenne; Fabrice Billet; Bernard Coulomb; Ian A Darby; Alexis Desmoulière
Journal:  Fibrogenesis Tissue Repair       Date:  2012-06-06
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.